Nanoparticles and the treatment of hepatocellular carcinoma

Nanoparticles and the treatment of hepatocellular carcinoma

Currently, liver cancer is the leading cause of cancer-related death worldwide, with a low 5-year survival rate, which will further decrease if advanced metastasis is present. Hepatocellular carcinoma (HCC) is the main type. However, due to the lack of specific symptoms in the early stages, it is mo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhang Ziyu, Cao Weihua, Li Xinxin, Deng Wen, Jiang Tingting, Wang Shiyu, Yang Liu, Lin Yanjie, Bi Xiaoyue, Lu Yao, Xu Mengjiao, Zhang Lu, Yi Wei, Xie Yao, Li Minghui
Format:	Article
Language:	English
Published:	De Gruyter 2024-12-01
Series:	Nanotechnology Reviews
Subjects:	hepatocellular carcinoma nanoparticles therapy tumor microenvironment drug delivery system combination with other therapies
Online Access:	https://doi.org/10.1515/ntrev-2024-0134
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nanoparticles and their application in the diagnosis of hepatocellular carcinoma
by: Li Xinxin, et al.
Published: (2024-11-01)

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)
by: Mingxuan Zhang, et al.
Published: (2025-01-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs
by: Demian van Straten, et al.
Published: (2025-01-01)

FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study
by: Yan-Cen Lu, et al.
Published: (2024-11-01)

Radionuclide-labelled nanoparticles for cancer combination therapy: a review
by: Na Sun, et al.
Published: (2024-11-01)

A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re‐Administering Atezolizumab and Bevacizumab
by: Satoru Hagiwara, et al.
Published: (2024-12-01)

Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review
by: Gui-Lin Xie, et al.
Published: (2025-01-01)

Targeted nanoparticle delivery unleashes synergistic photothermal and immunotherapeutic effects against hepatocellular carcinoma
by: Amal Babu, et al.
Published: (2024-12-01)

Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis
by: Zhu‐tao Wang, et al.
Published: (2024-12-01)

Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma
by: Yaqin Zhang, et al.
Published: (2024-12-01)

Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles
by: Qian An, et al.
Published: (2024-12-01)

Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study
by: Biling Gan, et al.
Published: (2025-02-01)

Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma
by: Yawen Yao, et al.
Published: (2024-12-01)

Salvage surgery after combination immunotherapy for initially unresectable or metastastic hepatocellular carcinoma: A retrospective clinical study
by: Jun-Shuai Xue, et al.
Published: (2023-12-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Mesoporous silica nanoparticles co-loaded with lysozyme and vancomycin for synergistic antimicrobial action
by: Nasrin Namdar, et al.
Published: (2024-11-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Curcumin and Metformin Infinite Coordination Polymer Nanoparticles for Combined Therapy of Diabetic Mice via Intraperitoneal Injections
by: Siwei Sun, et al.
Published: (2024-12-01)

Combination of Gene Therapy and Chemotherapy in a New Targeted Hybrid Nanosystem to Hepatocellular Carcinoma
by: Farinha D, et al.
Published: (2024-11-01)

Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion
by: Peng Huang, et al.
Published: (2025-01-01)

Promising first‐line immuno‐combination therapies for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
by: Feng Wen, et al.
Published: (2024-08-01)

Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
by: Zizhuo Wang, et al.
Published: (2025-01-01)

CLINICAL CASE OF BCLC STAGE B HEPATOCELLULAR CARCINOMA WITH A COMBINED TREATMENT
by: Zagorulko Aleksey Ivanovich, et al.
Published: (2024-12-01)

Conversion therapy for advanced biphenotypic hepatocellular carcinoma: A case report
by: Yu Zhang, et al.
Published: (2025-01-01)

Integrated multi-omics demonstrates enhanced antitumor efficacy of donafenib combined with FADS2 inhibition in hepatocellular carcinoma
by: Hui Li, et al.
Published: (2025-01-01)

Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review
by: Hye-Jin Yoo, et al.
Published: (2024-10-01)

Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy
by: Teng Zhang, et al.
Published: (2024-12-01)

Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy
by: Hicham Wahnou, et al.
Published: (2025-01-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma
by: Cong Luo, et al.
Published: (2025-01-01)

Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential
by: Nurhasni Hasan, et al.
Published: (2025-03-01)

Construction of a radiogenomic signature based on endoplasmic reticulum stress for predicting prognosis and systemic combination therapy response in hepatocellular carcinoma
by: Huai-Yu Wu, et al.
Published: (2025-01-01)

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy
by: Guandu Li, et al.
Published: (2025-12-01)

Research Progress on Using Nanoparticles to Enhance the Efficacy of Drug Therapy for Chronic Mountain Sickness
by: Boshen Liang, et al.
Published: (2024-10-01)

Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma
by: Xinyu Bi, et al.
Published: (2024-10-01)

From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment
by: Basingab FS, et al.
Published: (2025-01-01)

Gold Nanoparticles in Nanomedicine: Unique Properties and Therapeutic Potential
by: Furkan Eker, et al.
Published: (2024-11-01)

Characteristics and Antitumor Activity of Doxorubicin-Loaded Multifunctional Iron Oxide Nanoparticles in MEC1 and RM1 Cell Lines
by: Nino Maisuradze, et al.
Published: (2024-12-01)

Single-cell mitophagy patterns within the tumor microenvironment modulate intercellular communication, impacting the progression and prognosis of hepatocellular carcinoma
by: Zhengyan Li, et al.
Published: (2025-01-01)